Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens

A search of the Medline database and ASCO 2003 conference proceedings was conducted to identify clinical trials currently underway using single-agent therapy for renal cell carcinoma (RCC). Combination trials were identified using the ASCO 2003 conference proceedings. Fourteen Single-agent therapies employing different mechanisms of action were identified in the published literature: imatinib mesylate (Gleevec(R)); bevacizurnab (Avastin(R)); thalidomide (Thalomid(R)); gefitinib (ZD1839) (Iressa(R)); cetuximab (IMC-C225) (Erbitux(TM)); bortezomib (PS-341) (Velcade(R)); HSPPC-96 (Oncophage(R)); BAY 59-8862; ABT-510; G250; CCI-779; SU5416; PTK/ZK; and ABX-EGF. Six distinct fields of clinical research have emerged: monoclonal antibodies. small molecules. vaccines, second-generation taxanes, nonapeptides and immunomodulators. Five combination regimens. primarily biological response modifiers (interleukin-2 or interferon-alpha), chemotherapy- or thalidomide-based, were identified. All therapies demonstrated acceptable toxicity profiles. Clinical benefit was assessed based on each study's reported criteria: antitumor response (regression or stability) ranged from 5% to 71%. In the past several years, significant advances in the underlying biological mechanisms of RCC, particularly the role of tumor angiogenesis, have permitted the design of molecularly targeted therapeutics. Based on preliminary and limited studies, combination therapies offer the greatest clinical benefit in the management of this malignancy, although additional basic research is still warranted.